Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus

Area of Science:

• Oncology
• Gene Therapy
• Cancer Biology

Background:

• Traditional cancer gene therapies target tumor suppressor genes or exploit tumor-specific changes.
• Tumor heterogeneity and clonal evolution complicate these direct-acting therapies.
• The tumor microenvironment (TME) is a genetically stable component crucial for cancer progression and therapeutic resistance.

Purpose of the Study:

• To review recent advancements in gene therapy strategies targeting the tumor microenvironment (TME).
• To highlight promising TME-targeting approaches for cancer treatment.
• To explore the potential of TME-targeted therapies in overcoming challenges posed by tumor heterogeneity.

Main Methods:

• Review of current literature on TME-targeted gene therapies and armed oncolytic strategies.
• Analysis of approaches focusing on cancer stroma, tumor vasculature, and immune modulation within the TME.
• Evaluation of the efficacy and promise of different TME-targeting methods.

Main Results:

• TME-targeted strategies show significant promise, particularly those modulating the cancer stroma.
• Approaches reducing tumor vasculature and repolarizing the immunosuppressive microenvironment have demonstrated success.
• Focusing on the TME circumvents issues related to tumor genetic instability and clonal evolution.

Conclusions:

• Targeting the tumor microenvironment represents a viable and promising therapeutic avenue in cancer gene therapy.
• TME-targeting strategies offer an alternative to direct tumor cell-killing approaches, especially for heterogeneous cancers.
• Further development of TME-focused therapies holds potential for improved cancer treatment outcomes.